Strategies to Improve the Killing of Tumors Using Temozolomide: Targeting the DNA Repair Protein MGMT

被引：28

作者：

Jiang, G. ^{[1
,2
,3
]}

Li, L. -T. ^{[1
]}

Xin, Y. ^{[1
]}

Zhang, L. ^{[2
]}

Liu, Y. -Q. ^{[3
]}

Zheng, J. -N. ^{[1
]}

机构：

[1] Xuzhou Med Coll, Lab Biol Canc Therapy, Xuzhou 221002, Peoples R China

[2] Ctr Dis Control & Prevent Xuzhou City, Xuzhou 221006, Peoples R China

[3] Xuzhou Med Coll, Affiliated Hosp, Dept Dermatol, Xuzhou 221002, Peoples R China

来源：

CURRENT MEDICINAL CHEMISTRY | 2012年 / 19卷 / 23期

基金：

中国国家自然科学基金;

关键词：

Temozolomide; DNA repair; MGMT; cancer therapy; BASE EXCISION-REPAIR; PHASE-I TRIAL; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE INACTIVATION; IFN-BETA; PLUS O-6-BENZYLGUANINE; MISMATCH REPAIR; GLIOBLASTOMA CELLS; EXTREMITY MELANOMA; DOSE TEMOZOLOMIDE; DOWN-REGULATION;

D O I：

10.2174/092986712802002446

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Alkylating agents such as temozolomide (TMZ) are effective anticancer drugs for treating a variety of solid tumors including melanoma, glioma, and astrocytoma. TMZ exerts its effects mainly via the mutagenic product O-6-methylguanine, a cytotoxic DNA lesion. This damage may be repaired by the DNA repair enzyme O-6-methylguanine DNA methyltransferase (MGMT), a key player in the resistance of cancers to TMZ. Several strategies are presently being pursued to improve the killing of tumor cells by TMZ, with inhibition of MGMT being the most promising. In this review, we provide an overview of recent advances in this field.

引用

页码：3886 / 3892

页数：7

共 95 条

[1] Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication [J].

Aghi, M ;

Rabkin, S ;

Martuza, RL .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (01) :38-50

[2] Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter [J].

Alonso, Marta M. ;

Gomez-Manzano, Candelaria ;

Bekele, B. Nebiyou ;

Yung, W. K. Alfred ;

Fueyo, Juan .

CANCER RESEARCH, 2007, 67 (24) :11499-11504

[3]

Alvino E, 2006, INT J ONCOL, V29, P785

[4]

[Anonymous], INT J CANC

[5] RETRACTED: Genomic and Molecular Profiling Predicts Response to Temozolomide in Melanoma (Retracted Article. See vol 15, pg 3240, 2009) [J].

Augustine, Christina K. ;

Yoo, Jin Soo ;

Potti, Anil ;

Yoshimoto, Yasunori ;

Zipfel, Patricia A. ;

Friedman, Henry S. ;

Nevins, Joseph R. ;

Ali-Osman, Francis ;

Tyler, Douglas S. .

CLINICAL CANCER RESEARCH, 2009, 15 (02) :502-510

[6]

Barvaux VA, 2004, MOL CANCER THER, V3, P1215

[7] Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide [J].

Bobustuc, George C. ;

Baker, Cheryl H. ;

Limaye, Arati ;

Jenkins, Wayne D. ;

Pearl, Gary ;

Avgeropoulos, Nicholas G. ;

Konduri, Santhi D. .

NEURO-ONCOLOGY, 2010, 12 (09) :917-927

[8]

Bocangel D, 2009, ANTICANCER RES, V29, P3741

[9]

Boeckmann L, 2009, INT J CLIN PHARM TH, V47, P33

[10] DEFECTIVE MISMATCH BINDING AND A MUTATOR PHENOTYPE IN CELLS TOLERANT TO DNA DAMAGE [J].

BRANCH, P ;

AQUILINA, G ;

BIGNAMI, M ;

KARRAN, P .

NATURE, 1993, 362 (6421) :652-654

← 1 2 3 4 5 6 7 8 9 10 →